Relugolix in Combination with Androgen Receptor Pathway Inhibitors in the Treatment of Metastatic Prostate Cancer: A Clinical Perspective [0.03%]
高效利库肽联合雄激素受体途径抑制剂治疗转移性前列腺癌的临床思考
Tomas Buchler
Tomas Buchler
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, has been established as an effective androgen deprivation therapy (ADT) for advanced prostate cancer, offering advantages over traditional GnRH agonists. The comb...
Potential Mechanisms for Immunotherapy Resistance in Adult Soft-Tissue Sarcoma [0.03%]
成人软组织肉瘤免疫治疗抵抗的潜在机制
Zaina S Kret,Ryan J Sweder,Raphael Pollock et al.
Zaina S Kret et al.
Soft-tissue sarcomas represent a diverse group of rare malignancies originating from mesenchymal tissue, accounting for less than 1% of adult cancers in the USA. With over 13,000 new cases and around 5350 deaths annually, patients with meta...
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure [0.03%]
表皮生长因子受体突变亚型对表皮生长因子受体酪氨酸激酶抑制剂失败后非小细胞肺癌化疗免疫治疗和单纯化疗疗效的影响
Kenji Morimoto,Tadaaki Yamada,Naoki Furuya et al.
Kenji Morimoto et al.
Background: The efficacy of immune checkpoint inhibitor (ICI) monotherapy on non-small-cell lung cancer (NSCLC) varies by epidermal growth factor receptor (EGFR) mutation subtypes. However, the impact of these subtypes on...
The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials [0.03%]
罕见HRR基因变异预测PARP抑制剂治疗转移性去势抵抗性前列腺癌疗效的 meta 分析：基于随机对照试验的分析
Giada Pinterpe,Fortuna Migliaccio,Chiara Ciccarese et al.
Giada Pinterpe et al.
Background: Metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA1/2 mutations show significant responses to poly-ADP ribose polymerase inhibitors (PARPi), while the efficacy of these agents in patien...
Navigating the Landscape of Resistance Mechanisms in Antibody-Drug Conjugates for Cancer Treatment [0.03%]
抗体药物偶联物在癌症治疗中的抗性机制探讨
Gloria Lalli,Ilaria Sabatucci,Mariachiara Paderno et al.
Gloria Lalli et al.
Antibody-drug conjugates (ADCs) are an innovative approach in cancer therapy, combining the specificity of monoclonal antibodies (mAb) with the cytotoxic effect of chemotherapy agents. Despite the remarkable efficacy demonstrated in clinica...
Efficacy and Toxicity of Pemigatinib in Advanced Cholangiocarcinoma Harboring FGFR Fusions or Rearrangements: A Systematic Review and Meta-analysis [0.03%]
Pemigatinib治疗携带FGF受体融合或重排的晚期胆管癌的有效性和毒性：系统评价和 meta 分析
Erman Akkus,Hatime Arzu Yasar,Lorenza Rimassa et al.
Erman Akkus et al.
Background: The efficacy and safety of pemigatinib in advanced cholangiocarcinoma (aCCA) were presented in phase I-II trials and retrospective reports, with small sample sizes and variable results. ...
Zachary A Yochum,David A Braun
Zachary A Yochum
The treatment of renal cell carcinoma (RCC), a malignancy that is typically chemoresistant, has drastically evolved with the introduction of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs) and immune chec...
Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial [0.03%]
有关瑞卢戈利联合阿比特龙或安杂鲁马丁治疗晚期前列腺癌患者的安全性和耐受性：一项为期52周的临床试验数据
Jose De La Cerda,Laurence Belkoff,Kevin D Courtney et al.
Jose De La Cerda et al.
Background: The gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix is the only oral androgen deprivation therapy (ADT) indicated for advanced prostate cancer (aPC). Combining ADT with androgen receptor si...
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors [0.03%]
在结直肠癌和其他实体瘤患者中进行的抗CD47抗体Magrolimab与西妥昔单抗的1b/2期研究
Cathy Eng,Nehal J Lakhani,Philip A Philip et al.
Cathy Eng et al.
Background: Chemotherapy plus epidermal growth factor receptor (EGFR) inhibitors, such as cetuximab, is standard therapy for KRAS wild-type (KRASwt) colorectal cancer (CRC); however, responses are infrequent. Magrolimab i...
CIBMTR Registry Data on Inotuzumab Ozogamicin Treatment in Patients with ALL Who Proceeded to Hematopoietic Stem Cell Transplant-A Podcast [0.03%]
CIBMTR关于在进行造血干细胞移植的ALL患者中使用Inotuzumab Ozogamicin治疗的注册数据-播客
Marcos de Lima,David I Marks
Marcos de Lima
Inotuzumab ozogamicin (InO) was approved for the treatment of adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) on the basis of the phase 3 INO-VATE trial, which found that treatment-related mortality (TRM), primarily...